

Special Issue

Metal-Based Anticancer Drugs

Message from the Guest Editors

The use of metal complexes as anticancer agents revolutionized cancer treatment more than fifty years ago with the discovery of cisplatin, *cis*-[PtCl₂(NH₃)₂]. Further research led to clinical use of other platinum drugs, namely, carboplatin and oxaliplatin. The main deficiencies of the platinum-based drugs are their severe side effects and drug resistance. New metal-based anticancer drugs including essential and nonessential metals that have a different mode of action might be able to broaden the spectrum of treatable cancers, reduce toxic side effects, and overcome platinum resistance. The concept of selective targeting of cancer cells remains a challenge. Many new approaches to the design of innovative metal-based anticancer drugs are currently emerging. These include prodrugs, dual or multi-action prodrugs, etc. To enhance the efficacy of new metal-based drugs, prodrug and targeting strategies, as well as suitable drug delivery approaches, are being developed (design and synthesis of new ligands, nanocarriers, etc.). This Special Issue aims to highlight the progress in the field of development of new metal-based anticancer drugs.

Guest Editors

Prof. Dr. Vladimir Arion

Prof. Dr. Debbie C. Crans

Prof. Dr. Ignacio E. Leon

Deadline for manuscript submissions

closed (30 June 2022)



Inorganics

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1



mdpi.com/si/50363

Inorganics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
inorganics@mdpi.com

[mdpi.com/journal/
inorganics](https://mdpi.com/journal/inorganics)





Inorganics

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1



[mdpi.com/journal/
inorganics](https://mdpi.com/journal/inorganics)



About the Journal

Message from the Editor-in-Chief

Inorganic chemistry remains a lynchpin of modern chemistry, not only embracing the function and reactivity of combinations of most elements of the periodic table, but also providing a footing for studies of materials, catalysts, drugs, fuels and industrial chemicals. Arguably, the role and reach of inorganics in society have never been as great as today. Adventurous research at the heart and at the extremes of inorganic chemistry is vital to further advances and Inorganics offers authors the opportunity to publish exciting new research in an open access format.

Editor-in-Chief

Prof. Dr. Duncan H. Gregory

School of Chemistry, University of Glasgow, University Avenue, Glasgow
G12 8QQ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Inorganic and Nuclear) / CiteScore - Q2 (Inorganic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).